Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Lenvima has reduced the risk of disease progression or death by 34% in a ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

Three of Canada’s victories came at the World Cup: 37-4 in 1987 in New Zealand, 24-7 in 2003 in Australia and 25-20 in 2011 in New Zealand. The Canadian men’s next action is in November when ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

TOKYO - Tonga ran in three first-half tries and relied on some stingy second-half defence to defeat Canada 30-17 in the fifth-place match Saturday at the Pacific Nations Cup rugby tournament.

The Golf Today crew previews the upcoming Solheim Cup, breaking down Team USA and Team Europe and discussing how much ...

"We have many examples next to us we need to follow." While the U.S. men haven't reached the World Cup quarterfinals since 2002 and have never won the sport's top tournament, the American women ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...

As for the lead-in, European optimism lingered in the evening air on a day filled mostly with American jubilation. Ciganda ...

Three of Canada's victories came at the World Cup: 37-4 in 1987 in New Zealand, 24-7 in 2003 in Australia and 25-20 in 2011 in New Zealand. The Canadian men's next action is in November when they ...

Khang, Rose Zhang, and Allisen Corpuz moved the United States all won big, and the Americans prevented Europe from capturing ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...